A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants
Completed · Phase 1 · NCT06311656
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $231,484
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 69
About the trial
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Tested
- LY4100511 (DC-853) (drug), LY4100511 (DC-853) (drug), LY4100511 (DC-853) (drug), LY4100511 (DC-853) (drug), Placebo (drug)
- Dates
- Started 2024-03-19; completion 2024-10-04
- Results posted
- Not yet
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.
From ClinicalTrials.gov, last updated 2025-02-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $231,484 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Altasciences Professional Los Angeles $231,484
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.